Core Insights - Certara reported strong revenue and profitability for 2025, with organic software revenue growth of 7% and an adjusted EBITDA margin of 32%, exceeding expectations despite mixed bookings trends [4][5][3] Financial Performance - Full-year organic software revenue growth was 7%, aligning with the company's guidance of 6% to 8% [3][5] - Adjusted EBITDA margin finished at 32%, at the high end of the 30% to 32% target [5][4] - Trailing 12-month organic software bookings growth was 1%, with a year-over-year decline in software bookings in Q4 impacting this figure [6][5] Bookings Trends - Fourth-quarter bookings were characterized as mixed, with a notable rebound in December where services bookings increased by 17% [2][4] - Software bookings softened in Q4, leading to a 2026 outlook of "flat to up 4%" [5][6] - Specific customer dynamics, particularly among Tier 1 customers, affected software bookings, including reductions in Phoenix seat licenses due to customer reprioritization [6][7] Product Launches and Strategy - Three new software offerings were launched in Q4: Certara IQ for QSP, Phoenix Cloud, and a Pinnacle enhancement [5][9] - The transition to Phoenix Cloud changes revenue recognition from upfront to ratable, potentially impacting revenue growth in 2026 and 2027 [9][5] - Certara views AI as a competitive advantage, integrating AI across its platforms and products [10][11] Regulatory Services and Portfolio Focus - The regulatory services business is under evaluation by new CEO Jon Resnick, with considerations for keeping or selling the segment [12] - Certara's core focus remains on model-informed drug development (MIDD) and biosimulation, aiming to unify point solutions into broader offerings [13][14] Future Outlook - The company expects the first quarter of 2026 to be at the lower end of its guidance range, with opportunities to accelerate software revenue growth throughout the year [8][5] - Certara aims to maintain spending discipline while identifying cost avoidance measures to support its financial targets [15]

Core Insights - Certara's software bookings have shown a deceleration, with a 6% year-over-year decline in Q4, impacting the company's revenue growth outlook for 2026, which is projected to be flat to 4% [2][6][4] - The company reported that organic software revenue growth for 2025 was 7%, aligning with internal expectations, while EBITDA margin reached 32%, at the high end of guidance [3][4] - Certara's growth initiatives focus on biosimulation, particularly in quantitative systems pharmacology (QSP), Simcyp, and PBPK services, alongside AI and cloud offerings [5][11][12] Software Bookings and Revenue Outlook - The decline in software bookings is attributed to customer reprioritization and lagging study counts from slower clinical trial starts, which are expected to pressure future bookings [6][4] - Certara's organic trailing-twelve-month software bookings growth rate was approximately 1% for the previous year, indicating a need for improvement in this area [2][6] Services Performance - Certara's services segment has shown low-single-digit growth, averaging around 3% over the last three years, with a strong performance in December suggesting market stability [8][6] - The company noted that services bookings can be volatile, with significant fluctuations observed between quarters [8] Customer Segments and Market Dynamics - Tier-three customers, including biotechs, performed well, benefiting from an easing funding environment, while tier-one customers are expected to show stability despite past volatility [9] - The company anticipates that the reprioritization and headcount reductions affecting tier-one customers are largely behind them, although they may still impact near-term revenue [9] Growth Areas and AI Integration - Demand for model-informed drug development (MIDD) and biosimulation remains strong, with QSP and AI-enabled offerings being key growth areas [11][12] - Certara's acquisition of Vyasa in 2022 has allowed the integration of AI technology into its products, enhancing capabilities and customer value [12][13] Operational Priorities and Capital Allocation - Under new leadership, Certara aims to align its software and services offerings more closely, adopting a customer-centric approach [14] - The company plans to maintain an EBITDA margin of 30% to 32% while investing in R&D, particularly in MIDD and biosimulation, and has identified $10 million in cost avoidance for 2026 [15][16] Industry Trends and Opportunities - The industry is gradually shifting towards alternatives to animal model studies, presenting a significant opportunity for Certara in biosimulation, although adoption may take time due to risk aversion in pharma [17]

Summary of Certara FY Conference Call (March 10, 2026) Company Overview - **Company**: Certara (NasdaqGS:CERT) - **Industry**: Life Science Tools and Diagnostics Key Financial Performance - **Revenue**: Organic software revenue for FY 2025 was 7%, within the guidance range of 6%-8% [5] - **EBITDA Margin**: Achieved 32%, exceeding the guidance of 30%-32% [5] - **Bookings**: Mixed performance in Q4; December saw a strong 17% increase in services bookings [6][7] - **Software Bookings**: Trailing twelve-month organic software bookings were only 1%, indicating a decline year-on-year in Q4 [7][8] Market Dynamics - **Customer Behavior**: Notable reduction in seat licenses from tier one customers due to headcount reductions in Big Pharma [14][15] - **Study Counts**: Decreased clinical trial starts 18-24 months prior affected software bookings, particularly for the Pinnacle 21 platform [15][16] - **Seasonality**: Q4 showed strong discretionary spending, but services bookings remain lumpy historically [6][7] 2026 Guidance and Expectations - **Revenue Growth**: Expected to be flat to up 4% for 2026, with Q1 anticipated to be on the lower end of the guidance range [8][20] - **New Product Launches**: Three new software products launched in Q4, including Certara IQ for QSP and Phoenix Cloud, expected to drive growth [22][30] Product Development and AI Integration - **Certara IQ**: AI-enabled software for quantitative systems pharmacology (QSP), aimed at enhancing internal project throughput and customer sales [28][30] - **Phoenix Cloud**: Cloud version of the Phoenix platform, designed to transition customers from desktop to cloud, with positive initial reception [32][35] - **AI as Competitive Advantage**: Integration of AI technology from Vyasa is seen as a unique opportunity to enhance software offerings and maintain customer reliance [42][44] Regulatory Services and Strategic Evaluation - **Regulatory Writing Business**: High profit margins (20%-30%) but facing revenue declines; under evaluation for potential sale or retention [58][61] - **CEO's Focus**: New CEO Jon Resnick is assessing the regulatory business's status and its impact on shareholder value [55][57] Investment and Growth Strategy - **Customer-Centric Approach**: Emphasis on unifying software and services to better meet customer needs and enhance value proposition [72][73] - **Rule of Forty**: Company aims to align with the rule of forty, currently slightly below due to investments impacting margins [79][80] - **Cost Management**: Identified $10 million in cost avoidance opportunities while maintaining disciplined spending [83][85] Conclusion - Certara is navigating a transitional phase with mixed financial performance, focusing on new product launches and AI integration to drive future growth while evaluating its regulatory services segment for strategic decisions.

Summary of Certara Conference Call Company Overview - **Company**: Certara - **Industry**: Pharmaceutical services supply chain, focusing on biosimulation and regulatory services Key Points Q3 Results and Market Reaction - Certara experienced a slowdown in bookings at the end of Q3, which alarmed the market [4] - The company had lower-than-expected bookings, particularly in the regulatory business, which has been volatile [5] - Despite the slowdown, Certara reported strong results with tier three biotech clients, indicating a successful strategy focusing on venture capital companies [4][6] Regulatory Business Review - The regulatory business has been under strategic review for over a year due to volatility and current disruptions at the FDA [8] - Certara expects the regulatory environment to stabilize by 2026, but the business is not considered strategically important as it once was [9][11] Biosimulation and Market Trends - Certara holds a leadership position in biosimulation, benefiting from FDA initiatives to reduce animal testing [12][15] - The company is seeing increased interest in biosimulation from clients, particularly in monoclonal antibody development [13][14] - Certara's QSP (Quantitative Systems Pharmacology) business is growing, with the launch of Certara IQ aimed at becoming a standard software product in the market [35] Service Bookings and Client Dynamics - Tier three services have been strong, while tier one clients showed a slowdown in service bookings [20] - Certara has focused on financial sponsors and larger VCs to stabilize its client base [21] - The company has a large backlog of work, indicating potential for future growth as the market recovers [22] Pricing Environment - The current pricing environment is weaker, with mid-single-digit pricing increases on software products being tempered [24] - Certara is prioritizing the growth of biosimulation usage over immediate price increases [24] Product Development and Innovation - Certara has expanded its software offerings, including new versions of Simcyp targeted at preclinical and formulation scientists [28][29] - The company is evolving its software portfolio into a cloud-based platform, with plans for further integration and AI enhancements by 2026 [39][41] Economic and Regulatory Pressures - Certara faces hesitancy from clients to spend due to uncertainties in the regulatory environment and macroeconomic factors [44] - Despite these challenges, there is a long-term trend towards increased interest in modeling as a cost-effective solution in pharma [45][46] Conclusion - Certara is navigating a complex environment with both challenges and opportunities, particularly in biosimulation and regulatory services, while maintaining a strong pipeline and backlog of work [22][23]

Financial Data and Key Metrics Changes - Q3 2025 revenue was $104.6 million, reflecting a 10% year-over-year growth [4][14] - Adjusted EBITDA for Q3 was $35.2 million, with a margin of 34% [4][18] - Q3 bookings totaled $96.6 million, representing a 1% increase year-over-year [5][14] - The company narrowed its revenue guidance for 2025 to $415-$420 million, indicating 8%-9% growth compared to 2024 [5][20] Business Line Data and Key Metrics Changes - Software revenue reached $43.8 million, growing 22% year-over-year, with organic growth of 6% [10][15] - Service revenue was $60.8 million, up 3% year-over-year, driven by growth in QSP services [11][17] - Software bookings of $40.8 million increased 17%, while service bookings declined 9% [10][17] Market Data and Key Metrics Changes - Tier 1 services customers exhibited cautious spending behavior, impacting deal timelines [5][6] - The adoption of biosimulation solutions is increasing among large pharma customers, particularly in model-informed drug development [6][8] Company Strategy and Development Direction - The company is focused on investing in R&D and commercial teams, with R&D spending up 24% year-over-year [4][11] - Certara is expanding its software capabilities into discovery and preclinical phases, enhancing its product offerings [9][30] - The strategic review of the regulatory services business is nearing completion, with a definitive outcome expected by the end of 2025 [12] Management's Comments on Operating Environment and Future Outlook - Management noted a slowdown in deal completion timelines, particularly in regulatory services, due to large pharma customers adjusting their R&D focus [6][12] - There are positive leading indicators for the biosimulation market, with expectations for continued growth in 2026 [6][20] - Management expressed cautious optimism regarding macroeconomic stability and its potential positive impact on customer spending [35][46] Other Important Information - The company completed the Chemaxon acquisition, which has contributed positively to revenue and is expected to reach corporate average margins by year-end [9][19] - The company has repurchased approximately $41 million of stock as part of a $100 million share repurchase program [19] Q&A Session Summary Question: What is the dynamic regarding tier one services revenue or bookings? - Management noted delays in decision-making among tier one customers, with expectations for some deals to close in Q4 and others pushed to 2026 [23][24] Question: Can you comment on the gross profit outperformance? - Management attributed gross margin improvement to productivity gains and a favorable mix shift towards software [25][26] Question: How is the growth of QSP expected to evolve? - The company aims to standardize QSP modeling through its new software platform, Certara IQ, which is expected to drive efficiency and financial benefits [27][30] Question: What is the outlook for tier two and tier three services? - Tier two and tier three services have shown good growth, partially offsetting the headwinds faced by tier one services [64][65] Question: How does the company view the impact of AI on its business? - Management sees AI as a significant opportunity, with increased willingness among customers to adopt AI-enabled products [41][42]

Core Insights - Certara, Inc. has launched TFL Studio, a cloud-native module of its Phoenix Cloud solution, which enables the creation of Tables, Figures, and Listings (TFLs) 50% faster, enhancing collaboration among pharmacokinetic (PK) and pharmacodynamic (PD) scientists [1][3][4] Group 1: Product Features and Benefits - TFL Studio allows scientists to create high-quality TFLs in a user-friendly, no-code environment, significantly reducing the technical complexities involved in data handling and formatting [3][5] - The module integrates with Integral™, Certara's data repository, providing a unified source for PK/PD data, models, and visualizations [3] - A complementary module, AI PK Reports, will be released soon, utilizing GenAI to expedite the generation of draft PK reports from TFLs, reducing the time from days to minutes [3] Group 2: Market Position and Strategy - The introduction of TFL Studio is a strategic move to enhance drug discovery and development processes by leveraging AI and cloud technology, addressing inefficiencies in traditional TFL workflows [2][3] - Certara serves over 2,400 clients, including biopharmaceutical companies and regulatory agencies across 70 countries, indicating a strong market presence and demand for its innovative solutions [5]